“Strong Demand” For Lilly’s Weight-Loss Drug Overshadowed By Guidance Cut, Shares Fall Eli Lilly & Co. shares fell in premarket trading in New York after the company slashed its full-year profit outlook, citing increased research and development expenses, despite posting first-quarter revenue and earnings that beat analysts’ expectations, driven by strong demand for its anti-obesity drug, Mounjaro. Goldman analysts, including Asad Haider, provided clients with a first take on Lilly’s first-quarter earnings, indicating that 1Q25 results “slightly exceeded expectations.” LLY’s 1Q25 earnings slightly exceeded expectations, where, encouragingly, the tirzepatide franchise (Zepbound + Mounjaro) came in at $6.15bn ahead of GS/Visible Alpha… — Continue at ZeroHedge News : Read More
